Condition: Crohn Disease (CD) · Ileocolic Resection · Post-endoscopic Operative Reccurence · Sponsor: University Hospital, Clermont-Ferrand
Crohn's disease (CD) (\> 200,000 patients in France) is a chronic inflammatory disease that can lead to progression of intestinal destruction and impaired quality of life. Despite the widespread use of biotherapies, intestinal resections remain frequent (50% of patients over time). Unfortunately, surgery is not curative since 75% of patients experienced post-endoscopic operative recurrence (POR) (i.e., recurrence of ulcerations) during the first year after surgery. Prevention of endoscopic POR (defined as a Rutgeerts index ≥ i2) is essential because endoscopic POR is highly predictive of clinical POR (i.e., recurrence of CD-related symptoms): \> 40% and \> 80% within 5 years for a Rutgeerts index ≥ i2 or ≥ i3, respectively. The recommended management is to start treatment after surgery to avoid endoscopic POR, and to perform a colonoscopy at 6 months (M6) with therapeutic escalation if endoscopic POR. Despite anti-TNF or ustekinumab treatment, the endoscopic POR rate remains high (30-40% at M6) leading to \> 40% clinical POR despite therapeutic escalation (90 mg/4 weeks with ustekinumab) potentially due to late therapeutic escalation. Innovative strategies are therefore needed to prevent endoscopic POR, such as the use of fecal calprotectin, a non-invasive biomarker associated with endoscopic CD activity. We have previously demonstrated that its variation between surgery and M3 allows for a value at M3 predictive of endoscopic POR at M6. In this study, we hypothesize, for the…
This description comes directly from the study's public registry record.
Lise Laclautre · 334.73.754.963 · promo_interne_drci@chu-clermontferrand.fr
Always discuss trial participation with your own doctor first.
| CHU d'Amiens | Amiens, France | Not Yet Recruiting |
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| CHU de Lille | Lille, France | Not Yet Recruiting |
| HCL | Lyon, France | Not Yet Recruiting |
| AP-HM | Marseille, France | Not Yet Recruiting |
| CHU de Montpellier | Montpellier, France | Not Yet Recruiting |
| Chu de Nice | Nice, France | Not Yet Recruiting |
| CHU de Toulouse | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06972901